Glioblastoma News and Research RSS Feed - Glioblastoma News and Research

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed two new method of treatment patent applications with the United States Patent and Trademark Office to cover methods of treating brain tumors as well as cancers expressing a mutant form of RAS protein through administration of the Company’s lead compound, Plinabulin. [More]
Personalized gene therapy to fight against cancer

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor. [More]
2015 Minds Matter event raises funds to support brain tumor research

2015 Minds Matter event raises funds to support brain tumor research

One day in 2009, Maria Nijim's father got behind the wheel of his car and realized he couldn't see out of one eye. An MRI showed a tumor and then surgery confirmed a devastating diagnosis – glioblastoma – the most aggressive type of brain tumor. [More]
Researchers find way to enhance effects of immunotherapy in glioblastoma

Researchers find way to enhance effects of immunotherapy in glioblastoma

When cancer strikes, it may be possible for patients to fight back with their own defenses, using a strategy known as immunotherapy. According to a new study published in Nature, researchers have found a way to enhance the effects of this therapeutic approach in glioblastoma, a deadly type of brain cancer, and possibly improve patient outcomes. [More]
ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM). [More]
New radiation treatment for brain cancer implanted in first human being at CTRC

New radiation treatment for brain cancer implanted in first human being at CTRC

David Williams is the first human being ever to have a new radiation treatment implanted in the center of his brain tumor. [More]
Tetanus booster shot enhances effect of vaccine therapy for lethal brain tumors

Tetanus booster shot enhances effect of vaccine therapy for lethal brain tumors

An innovative approach using a tetanus booster to prime the immune system enhances the effect of a vaccine therapy for lethal brain tumors, dramatically improving patient survival, according to a study led by Duke Cancer Institute researchers. [More]
Chemotherapy, radiation therapy combination improves outcomes for people with low-grade brain cancer

Chemotherapy, radiation therapy combination improves outcomes for people with low-grade brain cancer

New clinical-trial findings provide further evidence that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer. The findings come from a phase II study co-led by a researcher at Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and researchers at the University of Maryland and at London Regional Cancer Program in Ontario, Canada. [More]
Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be presenting pre-clinical data on the lead candidate product, Cantrixil, at two upcoming conferences. [More]
Novogen's TRXE-009 therapy shows promise against brain cancer

Novogen's TRXE-009 therapy shows promise against brain cancer

Australian/US biotechnology company, Novogen Limited, today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer. [More]
MD Anderson scientists show why some brain cancer patients develop resistance to treatments

MD Anderson scientists show why some brain cancer patients develop resistance to treatments

Scientists at The University of Texas MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide. [More]
New cancer drug enters phase I clinical trials in humans

New cancer drug enters phase I clinical trials in humans

A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans. The drug, called PAC-1, first showed promise in the treatment of pet dogs with spontaneously occurring cancers, and is still in clinical trials in dogs with osteosarcoma. [More]
Researchers one step closer to understanding development of glioblastoma

Researchers one step closer to understanding development of glioblastoma

Glioblastomas are a highly aggressive type of brain tumor, with few effective treatment options. Moffitt Cancer Center researchers are one step closer to understanding glioblastoma development following the identification of a key protein signaling pathway involved in brain tumor stem cell growth and survival. [More]
New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

There are no effective available treatments for sufferers of Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always fatal, has a survival rate of only 6-18 months. [More]
Study results pave way for new clinical trial for glioblastoma patients

Study results pave way for new clinical trial for glioblastoma patients

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research. [More]
Researchers create new intraoperative probe for detecting cancer cells

Researchers create new intraoperative probe for detecting cancer cells

Brain cancer patients may live longer thanks to a new cancer-detection method developed by researchers at the Montreal Neurological Institute and Hospital - The Neuro, at McGill University and the MUHC, and Polytechnique Montréal. [More]
Franziska Michor named winner of Creative Promise Prize in Biomedical Science

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments. [More]
Drug similar to Gleevec may help tame some brain cancers

Drug similar to Gleevec may help tame some brain cancers

The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically designed to target an abnormal molecule--a fusion of two normal cell proteins--that fueled a tumor's growth. [More]
Drugs designed to target NHE9 protein could help fight glioblastoma

Drugs designed to target NHE9 protein could help fight glioblastoma

Applying lessons learned from autism to brain cancer, researchers at The Johns Hopkins University have discovered why elevated levels of the protein NHE9 add to the lethality of the most common and aggressive form of brain cancer, glioblastoma. Their discovery suggests that drugs designed to target NHE9 could help to successfully fight the deadly disease. [More]
Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Oncolytics Biotech submits Orphan Drug Designation for high grade gliomas in pediatric patients

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA") for REOLYSIN® for the treatment of high grade gliomas (HGG) in pediatric patients. [More]
Advertisement
Advertisement